Skip to main content
Equibles
KURA logo

KURA · Kura Oncology, Inc.

Track KURA — free

Use KURA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$13.11 +0.22 (+1.71%) At close · Sep 2
Russell 2000 member Rebalance outlook locked
Market Cap
$1.15B
Shares
88.96M

KURA metrics

65 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$13.11
Market cap
$1.15B

Price action

19 metrics
Price change (1W)
-5.2%
Price change (30D)
+40.3%
Price change (3M)
+43.7%
Price change (6M)
+51.6%
Price change (YTD)
+24.1%
Price change (1Y)
+63.2%
Trailing year
Price change (5Y)
-33.5%
52-week high
$13.59
52-week low
$7.40
Change from 52-week high
-5.2%
Change from 52-week low
+74.2%
Annualized volatility
60.6%
Beta
1.5
RSI (14D)
63.7
Price vs SMA 50
+17.8%
Price vs SMA 200
+31.9%
Avg volume (3M)
1.84M
Relative volume
0.8
Average dollar volume
$19.85M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
88.96M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
14.1×
reciprocal yield 7.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
14.8×
reciprocal yield 6.7%
P / book
23.7
reciprocal yield 4.2%
FCF yield
-10.2%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-25.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-12

Profitability

9 metrics
Gross margin
—
Operating margin
-411.9%
Trailing 12 months
Net margin
-384.3%
Gross profit (TTM)
—
Operating profit (TTM)
−$318.09M
Net income (TTM)
−$296.77M
Trailing 12 months
Diluted EPS (TTM)
$-3.37
FCF margin
-152.1%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.01

Growth

11 metrics
Revenue growth YoY
+36.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$77.22M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-612.8%
Return on assets
-50.5%
Debt / equity
0.2
Current ratio
4.7
EBITDA (TTM)
—
Free cash flow (TTM)
−$117.43M
Quick ratio
4.7
Interest coverage
-224.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$60.45M
Latest balance sheet
Cash & equivalents
$70.24M
Total assets
$587.79M
Total debt
$9.79M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$111.76M
Capital expenditures (TTM)
$5.67M
R&D (TTM)
$259.47M
SG&A (TTM)
—
Stock compensation (TTM)
$38.94M
R&D / revenue
336.0%
Stock compensation / revenue
50.4%

Ownership (13F)

3 metrics
13F filers
221
13F filer change QoQ
-1
Institutional ownership
98.3%

Short interest

3 metrics
Short interest
14.8%
Latest settlement · 8.8 days to cover
Days to cover
8.8d
Short-squeeze score
74 / 100

Insider activity

2 metrics
Net insider buying (90D)
$1.07M
Insider-sentiment score
88 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1422143 CUSIP 50127T109 13F (30d) 184 filings 178 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)